ANAinur F. Nasretdinov

Ainur F. Nasretdinov

*This is an algorithmically generated author record based on publicly available information.

Ainur F. Nasretdinov has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of alectinib in advanced ALK-positive non-small cell lung cancer: Results from the Russian multicenter KARL-005 study

    by D. T. Marinov, D. V. Perunov, L. N. Nefedova, I. S. Polyakov, A. F. Nasretdinov, A. A. Izmailov, A. V. Sultanbaev, M. I. Andrievskikh, R. A. Zukov, I. L. Obraz, et al.

    Introduction. Tyrosine kinase inhibitors, specifically alectinib, have significantly improved the prognosis for patients with advanced ALK-positive non-small cell lung cancer (ALK+ aNSCLC). National multicenter real-world data are essential to validate these outcomes within a broader clinical population. Aim. To evaluate the clinical efficacy of first-line alectinib in patients with ALK+ aNSCLC within routine clinical practice in the Russian Federation. Materials and methods. This multicenter retrospective study included patients who initiated first-line alectinib between 2020 and 2022. Primary endpoints included progression-free survival (PFS) and overall survival (OS) in the first-line setting. Secondary objectives assessed the prevalence of comorbidities and alectinib efficacy across clinical subgroups. Results. Data from 153 patients across 12 centers were analyzed. The median age was 56.7 years (range: 25.0–82.9), and 59.5% were female. At baseline, 21% of patients had an ECOG PS ≥ 2, and 20.3% presented with CNS metastases. Alectinib was administered as first-line therapy in 79 patients (51.6%), while 74 patients received it following prior chemotherapy. With a median follow-up of 47.8 months, the median PFS was 53.6 months (95% CI: 37.2 – NR) in the first-line cohort and 55.6 months (95% CI: 31.9 – NR) in the post-chemotherapy cohort. In the first-line group, median OS was not reached (5-year OS: 63.2%). For the post-chemotherapy group, median OS was 66.5 months (95% CI: 48.2 – NR; 5-year OS: 51.2%). Comorbidities were prevalent, notably cardiovascular disease (64.1%) and metabolic disorders (21.6%). Conclusion. Alectinib efficacy in Russian routine practice is comparable to the results of the landmark ALEX trial. The high prevalence of comorbidities highlights the need for a comprehensive, individualized approach to therapy selection in this population.

  • Open Access

    Intracranial activity characteristics of third-generation ALK inhibitor

    by A. F. Nasretdinov, A. V. Sultanbaev, K. V. Menshikov, V. E. Askarov, Sh. I. Musin, A. A. Izmailov, А. Ф. Насретдинов, А. В. Султанбаев, К. B. Меньшиков, В. Е. Аскаров, et al.

    Introduction. Intracranial involvement in ALK-positive non-small cell lung cancer is associated with poor prognosis and resistance to certain therapies due to the blood-brain barrier. Third-generation tyrosine kinase inhibitors, particularly lorlatinib, demonstrate high efficacy due to their lipophilicity and low affinity for P-glycoprotein. Aim. To present a clinical case of successful use of lorlatinib for controlling intracranial progression in a patient with ALKpositive non-small cell lung cancer after developing resistance to alectinib, as well as to analyze the factors contributing to the antitumor response in the central nervous system. Mat erials and methods. We describe a case of a female patient born in 1963 diagnosed with stage IVB peripheral lung adenocarcinoma (T1cN3M1c, oss, cer), ALK-positive. After disease progression on alectinib therapy (development of multiple brain metastases), lorlatinib was prescribed at a dose of 100 mg per day, followed by dose reduction to 75 mg per day. Efficacy was assessed using brain MRI and chest CT. R e s u l t s and di sc u ssi on. While receiving lorlatinib, the patient achieved a complete intracranial response, confirmed by MRI at 3, 6, 9, and 12 months of follow-up. The duration of central nervous system tumor growth control after switching therapy was 12 months or more. Adverse events (grade 1 hypercholesterolemia, grade 2 peripheral neuropathy and edema) were managed by dose reduction to 75 mg per day without loss of efficacy. Overall lorlatinib showed high intracranial and an expected toxicity Conclusion. Lorlatinib is a highly effective agent for overcoming intracranial resistance in patients with ALK-positive lung cancer who progress on alectinib. This case supports the use of lorlatinib in the second-line setting for isolated central nervous system progression, potentially avoiding radiotherapy and its associated complications.

  • Open Access

    Cholangiocarcinoma: A clinical case of long-lasting response to immunochemotherapy

    by K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, A. A. Volkov, I. A. Menshikova, A. F. Nasretdinov, A. F. Aymatova, A. V. Sultanbaev, I. A. Tuzankina

    Cholangiocellular carcinoma is a heterogeneous group of malignant neoplasms of the biliary tract. It accounts for approximately 3% of all gastrointestinal tumors and is the second most common primary liver tumor after hepatocellular carcinoma. Surgery is the only cure. Surgical treatments are among the most complex in hepatopancreatobiliary surgery. Standard first-line therapy with gemcitabine-based chemotherapy has demonstrated a modest improvement in survival in patients with advanced cholangiocellular carcinoma. Despite its role as the cornerstone of first-line therapy, chemotherapy produces suboptimal response rates, and overall survival highlights the urgent need for improved therapeutic strategies. The TOPAZ-1 trial, which included an immuno-oncology agent, demonstrated an improvement in overall survival. In the case described above, the patient first presented for this condition in 2022. After diagnosis verification, chemoembolization and surgical treatment were performed. Disease progression began in 2023. Based on the progression, chemotherapy in combination with durvalumab was initiated. In the case of local progression, a course of stereotactic radiotherapy was administered. This clinical case demonstrates the results of combining systemic therapy and local control methods. Progression-free survival with durvalumab therapy was 26 months. Thus, this option demonstrated the potential of modern immunochemotherapy and stereotactic radiotherapy.

  • Open Access

    The importance of the level of T-cell receptor excision circles and κ-deletion B-cell receptor excision circles in the effectiveness of therapy for metastatic ovarian cancer

    by Alexander V. Sultanbaev, Irina A. Tuzankina, Konstantin V. Menshikov, Ainur F. Nasretdinov, Nadezhda I. Sultanbaeva, Shamil I. Musin, Mikhail V. Sultanbaev, Angelina A. Izmailova, Evgeniy A. Troshenkov, Dmitry A. Kudlay

    Background. Antigen load, expression of programmed cell death ligand 1 and T-cell receptors play a key role in the formation of specific antitumor immunity. The marker of the diversity of the repertoire of receptors of immunocompetent cells to various antigens are T-cell receptor excision circles (TREC) and the κ-deletion B-cell receptor excision circles (KREC), which are extrachromosomal DNA structures. Aim. To evaluate the effect of the diversity of TREC and KREC on the effectiveness of olaparib therapy for generalized ovarian cancer. Materials and methods. The study included 40 patients undergoing treatment at the Republican Clinical Oncological Dispensary (RCOD) of the Ministry of Health of the Republic of Bashkortostan for ovarian cancer. The local ethics committee of RCOD approved on July 21, 2022 the protocol “IO-001” of a single-center non-randomized open clinical trial entitled “Determination of TREC and KREC in patients with malignant neoplasms of various localizations”. All patients were prescribed olaparib therapy (international non-proprietary name). To identify mutations in genes associated with HRD (homologous recombination deficiency), next-generation sequencing by allele-specific polymerase chain reaction was used. Before the start of therapy, the level of TREC and KREC was assessed. Results. Before the start of therapy in the general population, the median TREC was 9.6 copies/105 cells, the median KREC was 183.8 copies/105 cells. The minimum and maximum TREC levels were 0.07 copies/105 cells and 215 copies/105 cells, respectively. The minimum and maximum KREC levels were 2.8 copies/105 cells and 1559.42 copies/105 cells, respectively. In the group of patients with disease progression, the level of TREC was low. According to the results of the study, disease progression was predicted at a TREC value 13.23 copies/105 cells. The obtained results indicate a significantly low level of KREC before the start of therapy in patients who progressed during therapy. Conclusion. The prognostic role of TREC and KREC has been determined. Further research will allow us to take into account changes in TREC and KREC indicators in dynamics and use the prognostic value of these changes in the treatment of ovarian cancer. Threshold levels of TREC (13.23 copies/105 cells) and KREC (251.04 copies/105 cells) were detected, below which disease progression was observed.

  • Levels of T-cell receptor excision rings and B-cell κ-deletion element in healthy individuals in different age groups

    by A.V. Sultanbaev, I.A. Tuzankina, N.I. Sultanbaeva, K.V. Menshikov, Sh.I. Musin, A.F. Nasretdinov, I.A. Menshikova, F.S. Bilalov, M.V. Sultanbaev, D.A. Kudlay

    In pediatric practice, quantitative determination of T-cell receptor excision circles (TREC) and B-cell κ-deletion element (KREC) is widely used for diagnostics of primary immunodeficiency states. The issue of diagnostic significance of TREC and KREC studies in the adult population has been poorly studied so far. The purpose of this study is to determine the age-related physiological levels and thresholds of TREC and KREC levels in men and women. We studied the level of TREC and KREC in 213 conditionally healthy individuals aged 18 to 82 years. The study included 104 (49.0%) men and 109 (51.0%) women. Peripheral venous blood was collected. TREC and KREC concentrations were determined in men and women. The principle of the method is based on the quantitative determination of the content of TREC and KREC DNA is performed using the process of amplification of TREC and KREC DNA regions using primers and hybridization probes specific to these regions and Taq DNA polymerase, followed by determination of the accumulation of a specific fluorescent signal in real time. The linear range of quantitative determination of the copy number of TREC and KREC determined using the calibrators of the IMMUNO-BIT reagent kit is from 1x103 to 1x107 copies/ml. Statistical calculations were performed using the StatTech v. 4.7.1 program (Russia). There was a difference in the level of TREC between the groups of men and women. An inverse age-related dependence of the level of TREC and KREC on age was established, indicating a decrease in the number of TREC and KREC during life. Conclusions.The results of the study show that the levels of TREC and KREC decrease with age. In different age groups of donors, we obtained reference values of physiological levels of TREC and KREC. Quantitative determination of TREC and KREC levels should be introduced into routine practice, since it is a very informative method for diagnosing diseases and therapeutic monitoring.

  • Open Access

    Levels of T-cell Receptor Excision Circles and B-cell κ-deletion Element in Patients with Stages I–III Ovarian Cancer

    by Alexander V. Sultanbaev, Irina A. Tuzankina, Konstantin V. Menshikov, Ainur F. Nasretdinov, Shamil I. Musin, Alfiia A. Fatikhova, Nadezhda I. Sultanbaeva, Adel A. Izmailov, Mikhail V. Sultanbaev, Dmitry A. Kudlay

    Introduction. Ovarian cancer is the ninth most common malignant neoplasm. This condition often causes severe complications, such as loss of reproductive organs, which is particularly characteristic of hereditary forms of the cancer. At present, a wide range of ovarian cancer treatments is available, including targeted therapy; however, optimal immunotherapy regimens are still lacking. The development and progression of ovarian cancer are largely determined by impaired immune surveillance. A factor influencing the effectiveness of immune surveillance of the tumor is a diverse repertoire of T-cell and B-cell receptors. The aim of this study was to investigate the levels of T-cell receptor excision circles (TREC) and κ-deleting recombination excision circles (KREC) in patients with stage I–III ovarian cancer. Materials and methods. Levels of TREC and KREC were analyzed in 42 patients with ovarian cancer who underwent radical treatment. The study included patients aged 23 to 74 years. Results and discussion. The median TREC level (copies/10⁵ cells) was 16.04 [Q1–Q3: 2.14–37.31], and the median KREC level (copies/10⁵ cells) was 130.06 [Q1–Q3: 0.34–917.00]. Following radical treatment, 17 patients (40.5%) experienced disease recurrence. The median recurrence-free survival was 19 months, with the earliest recurrence observed 7 months after surgery. Our findings corroborate previous studies indicating an association between malignant tumor progression and excision circle levels. The results also demonstrated a decrease in TREC and KREC levels with increasing patient age, as well as a clear trend toward recurrence in patients with reduced blood levels of TREC and KREC. Conclusion. Based on our results, in patients with recurrent ovarian cancer, blood levels of TREC and KREC are low. These changes reflect the presence of immunodeficiency conditions, which in turn indicate reduced antitumor.

  • Results of the use of immune checkpoint inhibitors in the treatment of small cell lung cancer in real-life clinical practice: results of a single-center observational study

    by A.V. Sultanbaev, I.A. Tuzankina, A.F. Nasretdinov, K.V. Menshikov, V.E. Askarov, Sh.I. Musin, N.I. Sultanbaeva, A.A. Izmailov, I.A. Menshikova, D.A. Kudlay

    Small cell lung cancer (SCLC) is an aggressive tumor with early metastasis and a low 5-year survival rate (6.4%). Despite the use of PD-L1 inhibitors (atezolizumab, durvalumab) in combination with chemotherapy, outcomes remain unsatisfactory due to resistance and patient heterogeneity. Objective. To evaluate the effectiveness of immunochemotherapy (atezolizumab+carboplatin/etoposide) in real-world clinical practice in patients with metastatic SCLC. Material and methods. Data from 98 patients (87 men, 11 women, median age 62 years) over 50 months (2020—2024) were analyzed. Treatment regimen: carboplatin (AUC5), etoposide (100 mg/m²), and atezolizumab (1200 mg) every 3 weeks (4 cycles), followed by maintenance therapy. Progression-free survival (PFS), overall survival (OS), and the impact of metastases/comorbidities were assessed. Results. Median PFS was 6 months, OS was 12 months. Partial response was observed in 60.2%, stable disease in 23.5%, disease progression in 13.3%, and complete response in 3.1%. Metastases in the liver, bones, peritoneum, and kidneys significantly reduced PFS and OS (p< 0.05). Comorbidities had no significant impact. Conclusion. The combination of atezolizumab with chemotherapy demonstrates efficacy comparable to clinical trial data, but outcomes depend on metastasis location. Metastatic involvement of the liver, bones, and peritoneum is associated with a worse prognosis, highlighting the need for personalized treatment approaches.


  • Open Access

    Efficacy of combination immunotherapy in patients with generalized uveal melanoma: real clinical practice

    by A. V. Sultanbaev, I. A. Tuzankina, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, Sh. I. Musin, V. M. Zabelin, R. T. Ayupov, V. E. Askarov, R. R. Rakhimov, et al.

    Introduction. Uveal melanoma is a rare malignant neoplasm that develops from melanocytes of the choroid of the eyeball. It occupies a leading position in the structure of intraocular malignant neoplasms.Aim. Тo analyze real-world clinical practice data on the use of nivolumab in combination with ipilimumab to treat patients with metastatic uveal melanoma.Materials and methods. Fifteen patients with metastatic uveal melanoma received therapy with nivolumab and ipilimumab. The median age of patients was 53 years, the minimum age was 24 years, and the maximum was 71 years. The analysis included 9 (60%) men and 6 (40%) women. Evaluation of the functional status showed that 4 (26.7%) patients had ECOG 0 points, 6 (40%) – ECOG 1 and 5 (33.3%) – ECOG 2.Results. The median relapse-free survival after enucleation of the eye was 61 months. Objective response to immunotherapy was achieved in 33.3% of patients, and the disease control rate was 86.6%. However, 4 (26.6%) patients discontinued therapy due to hepatotoxicity. The study noted that the median overall survival from the start of therapy with nivolumab in combination with ipilimumab reaches 8 months. It was found that the functional status of patients and the response to therapy are important predictors of survival, where patients with better indicators have a significantly higher life expectancy. Thus, patients with ECOG 0 show a median overall survival of 18 months.Conclusion. Immune checkpoint inhibitors remain the mainstay of treatment for patients with metastatic uveal melanoma. Combined immunotherapy with nivolumab and ipilimumab can be considered as a possible treatment option for this category of patients in conditions of limited therapeutic options.

  • Open Access

    Efficacy of immune drugs in maintenance therapy after radical chemoradiation treatment of lung cancer: Results of real clinical practice

    by A. V. Sultanbaev, I. A. Tuzankina, A. F. Nasretdinov, Sh. I. Musin, N. I. Sultanbaeva, K. V. Menshikov, I. A. Menshikova, A. A. Izmailov, D. A. Kudlay

    Introduction. Durvalumab is the first immunotherapy drug proven effective as consolidation therapy after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The PACIFIC and PACIFIC-R trials confirmed significant survival benefits, but real-world data, including from Russian studies, show variability in outcomes.Aim. To evaluate the effectiveness of durvalumab in real-world clinical practice in patients with stage IB-IIIC NSCLC after definitive CRT.Materials and methods. A retrospective analysis of 81 patients (2021–2024) who received durvalumab after CRT (60 Gy ± 10%). Median age was 63 years; 78% were smokers. Histology: 75% squamous cell carcinoma, 23% adenocarcinoma. PD-L1 status: 22% ≥ 1%, 18% unknown. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method.Results. Median PFS was 14 months (95% CI: 12–22); OS at 28 months was 52%. Better PFS in squamous cell carcinoma (19 vs. 13 months in adenocarcinoma), but not statistically significant (p = 0.08). Significant PFS improvement in PD-L1+ (HR = 0.43; p = 0.025), but not OS (p = 0.053). Higher PFS in stages I–IIIA (22 vs. 12 months in IIIB-IV; p = 0.01), but no OS difference. Grade 3–4 adverse events in 15% (pneumonitis – 4.9%).Conclusion. Durvalumab demonstrates clinically meaningful PFS improvement, especially in PD-L1+ patients and early-stage disease. However, its impact on OS requires further follow-up. Results align with PACIFIC but highlight the importance of individual factors (histology, PD-L1, stage).

  • Open Access

    Results of using revascularized flaps in patients with oral cancer after neoadjuvant chemotherapy

    by Sh. I. Musin, K. V. Menshikov, A. V. Sultanbaev, N. A. Sharafutdinov, M. M. Zamilov, R. T. Ayupov, A. F. Nasretdinov, А. О. Гузь, D. M. Fatkullin, A. N. Rudyk

    Introduction. In Russia, cancer of the oral mucosa is diagnosed in more than 9500 patients every year. In 65–70 % of cases, the disease is diagnosed at stages III–IV. Despite the use of combination treatment, prognosis in patients with stage III and IVA oral mucosa cancer remains unfavorable. Neoadjuvant chemotherapy is considered a strategy to decrease the risk of distant metastasis, decrease tumor volume, and affect the status of surgical resection margins.Aim. To evaluate the results of using revascularized flaps in patients with resectable stage III and IVA cancer of the oral mucosa who received neoadjuvant chemotherapy.Materials and methods. Retrospective analysis of data of 41 patients who underwent surgery in 2020–2023 at the Republican Clinical Oncological Dispensary (Ufa) was performed. All patients underwent R0 resection with subsequent defect reconstruction using revascularized flaps. Two groups were compared: primary patients (n = 31) and patients who received neoadjuvant therapy per the DCF (docetaxel, cisplatin, 5‑fluorouracil) (n = 10) scheme.Results. Overall rate of complications in the groups of primary patients and patients receiving neoadjuvant therapy per the DCF scheme was 16.1 and 20 %, respectively (p = 0.398), however the rate of flap loss was significantly higher in patients who underwent neoadjuvant chemotherapy: 40 % versus 9.7 % (p = 0.047). Recurrence rate in the neoadjuvant chemotherapy group was 10 %, in the group without neoadjuvant therapy it was 38.7 % (p = 0.129).Conclusion. Neoadjuvant chemotherapy can be associated with higher risk of microvascular complications and flap loss but it decreases the recurrence rate. Therefore, further search for the optimal treatment strategy for patients with cancer of the oral mucosa is necessary.